Marker Therapeutics - Our Science
Our Science
Publications

Publications

  • T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. American Society of Clinical Oncology. View

  • Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS post-allogeneic transplant.. American Society of Hematology. View

  • The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. Science Translational Medicine.

  • Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood Journal.

  • Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood Journal.

  • Activity of Broad-Spectrum T Cells as Treatment for AdV, EBV, CMV, BKV, and HHV6 Infections after HSCT. Science Translational Medicine.

  • Activity of Broad-Spectrum T Cells as Treatment for AdV, EBV, CMV, BKV, and HHV6 Infections after HSCT. Science Translational Medicine.

  • Optimizing the production of suspension cells using the G-Rex “M” series. The American Society of Gene & Cell Therapy.

  • Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant. The National Institute of Health.

  • Generation of Tumor Antigen-Specific T Cell Lines from Pediatric Patients with Acute Lymphoblastic Leukemia—Implications for Immunotherapy. Clinical Cancer Research.

  • Accelerated production of antigen-specific T-cells for pre-clinical and clinical applications using Gas-permeable Rapid Expansion cultureware (G-Rex). The National Institute of Health.